# Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

> **NCT05194735** · PHASE1,PHASE2 · TERMINATED · sponsor: **Alaunos Therapeutics** · enrollment: 8 (actual)

## Conditions studied

- Gynecologic Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Non-small Cell Lung Cancer
- Cholangiocarcinoma
- Ovarian Cancer
- Endometrial Cancer
- Ovarian Carcinoma
- Ovary Neoplasm
- Squamous Cell Lung Cancer
- Adenocarcinoma of Lung
- Adenosquamous Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Neoantigen specific TCR-T cell drug product
- **BIOLOGICAL:** Aldesleukin (IL-2)

## Key facts

- **NCT ID:** NCT05194735
- **Lead sponsor:** Alaunos Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-04
- **Primary completion:** 2023-08-14
- **Final completion:** 2023-08-14
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Funding
- **Last updated:** 2025-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05194735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05194735, "Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05194735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*